New hope for Hard-to-Treat breast cancer: phase 3 trial launches
Disease control
Not yet recruiting
This phase 3 trial compares a new drug called 9MW2821 to standard chemotherapy in 356 people with advanced triple-negative breast cancer who have already received certain prior treatments. The main goal is to see if the new drug helps people live longer. Participants will receive…
Phase: PHASE3 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC